• Publications
  • Influence
Advances in malignant mesothelioma.
Malignant mesothelioma is an aggressive tumor of serosal surfaces, such as the pleura and the peritoneum. This tumor was once rare, but its incidence is increasing worldwide, probably as a result ofExpand
  • 957
  • 34
  • PDF
Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
Malignant pleural mesothelioma (MPM) is a highly lethal cancer of the lining of the chest cavity. To expand our understanding of MPM, we conducted a comprehensive integrated genomic study, includingExpand
  • 155
  • 19
  • PDF
Cross-priming in health and disease
Cross-priming is an important mechanism to activate cytotoxic T lymphocytes (CTLs) for immune defence against viruses and tumours. Although it was discovered more than 25 years ago, we have onlyExpand
  • 377
  • 17
  • PDF
Mesothelin-family proteins and diagnosis of mesothelioma
BACKGROUND Mesothelioma is a highly aggressive tumour for which there are no reliable serum tumour markers. Identification of such a marker would be useful in diagnosis of mesothelioma and forExpand
  • 520
  • 16
Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
Inhibitory molecules of the B7/CD28 family play a key role in the induction of immune tolerance in the tumor microenvironment. The programmed death-1 receptor (PD-1), with its ligands PD-L1 andExpand
  • 252
  • 14
  • PDF
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
Cytotoxic chemotherapy is generally considered immunosuppressive, with neutropenia and lymphopenia being common adverse side effects. In this context, we have shown previously that the cytidineExpand
  • 396
  • 12
  • PDF
Immunotherapy and chemotherapy — a practical partnership
This article discusses how recent data have altered the way we understand how dying tumour cells, particularly those killed by chemotherapy, engage with antitumour immune responses. These data haveExpand
  • 588
  • 11
Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells1
Cross-presentation of cell-bound Ags from established, solid tumors to CD8 cells is efficient and likely to have a role in determining host response to tumor. A number of investigators have predictedExpand
  • 406
  • 11
Establishment of a murine model of malignant mesothelioma
Malignant mesothelioma (MM) is an aggressive tumour of the serosal cavities which is associated with previous asbestos exposure and is generally found to be resistant to conventional forms ofExpand
  • 169
  • 10
Tumor-Specific CD4+ T Cells Have a Major “Post-Licensing” Role in CTL Mediated Anti-Tumor Immunity1
A number of tumor studies have indicated a link between CD4 help and the magnitude and persistence of CTL activity; however, the mechanisms underlying this have been largely unclear. To evaluate andExpand
  • 364
  • 8